Can Kinase Inhibitors and Immunomodulators Replace Chemotherapy? No

Slides:



Advertisements
Similar presentations
Palumbo A et al. Proc ASH 2013;Abstract 536.
Advertisements

What is the Optimal Approach to CLL, BR vs. FCR/FR?
Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
13th Annual Hematology & Breast Cancer Update Update in Lymphoma
Brown JR et al. Proc ASH 2013;Abstract 523.
Goede V et al. Proc ASCO 2013;Abstract 7004.
New Data for Old Drugs in CLL Kanti R. Rai MD Joel Finkelstein Cancer Foundation Professor of Medicine Hofstra North Shore-LIJ School of Medicine Hempstead,
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,
Spotlight on Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma: European and US Perspectives on the Evolving Standard of Care Bruce Cheson,
Lymphoma & Myeloma 2014 October 24, 2014 Obinutuzumab: Analysis of it’s Pivotal Data Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma.
Kovacs G et al. Proc ASH 2014;Abstract 23.
Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.
Update: Chronic Lymphocytic Leukemia ASHASH.
Copyright © 2011 Research To Practice. All rights reserved. Interest in Topics Related to the Treatment of Patients with CLL (Percent Responding 9 or 10)
Lessons from the CLL8 study Adapted from Hallek, oral presentation, ASH 2008 FCR is superior to FC in most cytogenetic subgroups with regard to: Response.
Rituximab efficacy in other haematological malignancies Christian Buske.
Should Chlorambucil Be Used with Obinutuzumab in Untreated CLL? Answer: YES! Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma Translational.
Kanti R. Rai, MD NSLIJ-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Hematology Highlights 2013 Expert Reviews of the.
A Phase II Study of Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia Xavier Badoux, William Wierda, Susan O'Brien,
Head-to-Head Comparison of Obinutuzumab (GA101) plus Chlorambucil (Clb) versus Rituximab plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and.
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.
How to Treat CLL in 2014: Overview of CLL
Correlation of Hand-Foot Skin Reaction (HFS) with Treatment Efficacy in Pancreatic Cancer (PC) Patients (pts) Treated with Gemcitabine/Capecitabine plus.
Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.
Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
Second Interim Analysis of a Phase 3 Study of Idelalisib Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient.
Ibrutinib in Combination with Rituximab (iR) Is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High- Risk Chronic Lymphocytic.
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
Results from a Randomized Phase III Trial of Decitabine versus Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed.
Rituximab Maintenance After Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida Phase III RESONATE-2: Frontline Ibrutinib.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida Venetoclax Monotherapy in R/R CLL With del(17p)
Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma New Findings in Hematology: Independent.
Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC
Geisler C et al. Proc ASH 2011;Abstract 290.
MRD testing: which platforms, which patients?
Vose JM et al. Proc ASH 2011;Abstract 661.
Which is the optimal approach: BR or FCR/FR?
CCO Independent Conference Highlights
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
Palumbo A et al. Proc ASH 2012;Abstract 200.
Multiple Myeloma in the Non-transplant Setting
Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma
Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
CALGB/Alliance 50303: R-CHOP vs DA-EPOCH-R in Newly Diagnosed Diffuse Large B-Cell Lymphoma New Findings in Hematology: Independent Conference Coverage.
Managing the Otherwise Healthy Patient With CLL
Mateos MV et al. Proc ASH 2013;Abstract 403.
Goede V et al. Proc ASH 2014;Abstract 3327.
WHAT IS THE BEST Front-Line REGIMEN for Patients With CLL
Fowler NH et al. Proc ASCO 2010;Abstract 8036.
Barrios C et al. SABCS 2009;Abstract 46.
Ferrajoli A et al. Proc ASH 2010;Abstract 1395.
Badoux X et al. Proc ASCO 2010;Abstract 6508.
Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk.
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial by Peter Dreger,
Vitolo U et al. Proc ASH 2011;Abstract 777.
What is the optimal management of a 43-year-old man with high-risk FL not in CR after R-chemo? Answer: Radioimmunotherapy Peter Martin, M.D. The Charles,
Faderl S et al. Proc ASCO 2011;Abstract 6503.
What is the best frontline regimen for CLL patients
LBA-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy.
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.
CLL : Integrating novel therapies into frontline and salvage regimens
How should anti-CD20 monoclonal antibodies be utilized in CLL?
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis by.
Presentation transcript:

Can Kinase Inhibitors and Immunomodulators Replace Chemotherapy? No Michael J. Keating MD Anderson Cancer Center Presented by: Susan O’Brien

Response to FC + Rituximab (NCI-WG: 300 Patients) Response* # Pts. ( % ) CR 217 (72%) Nodular PR 31 (10%) 95% PR 37 (12%) No Response 13 ( 4%) Early Death 2 ( 1%) * Evaluated 6 months after last course

CLL8 Study Design 6 courses FCR R FC Patients with untreated, active CLL, and good physical fitness (CIRS ≤6, creatinine clearance ≥70 mL/min) R FCR FC 6 courses Follow- up C1 C2 C3 C4 C5 C6 Updated results of the 2nd analysis Median observation time 37.7 months. Hallek et al. Lancet. 2010;376:1164-1174.

FC (%) FCR (%) P FC vs FCR: Response CR 23 45 <0.01 CRu 5 3 0.22 CRi 2 0.52 nPR 0.15 PR 50 40 OR 85 93 Hallek et al. Lancet. 2010;376:1164-1174.

CLL8 Update PFS N-817 Median PFS: FC: 32,9 months FCR: 57,9 months HR: 0,56 95%CI:0.465-0.673; P<0.0001 Fink, et al. ASH 2011, Abstract 977

CLL8 Trial: 1st Line FC vs. FCR Overall survival: HR= 0.68; p= .001 Median follow-up= 70 months Fischer et al. Updated, ASH 2012, Abstract 435

Are there any patients with CLL for whom FCR is NOT the Standard of Care?

CLL8 Genetic Analyses: PFS EHA Educational Talk 2013 21 September 2008 CLL8 Genetic Analyses: PFS FC FCR CLL8 Investigator Meeting 21 September 2008

CLL8 Study Design 6 courses FCR FC Follow R up Patients with untreated, active CLL and good physical fitness (CIRS  6, Creatinine clearance  70 ml/min) Updated results of the 2nd analysis Median observation time 37.7 months. Hallek et al Lancet 2010;376:1164-74

CLL8: Side Effects: the Effect of Age FC FCR < 70 yrs n = 359  70 yrs n = 37 p < 70 yrs n = 361  70 yrs n = 43 Total AEs gr 3/4 61.0% 78.4% 0.04 75.6% 83.7% 0.24 Anemia 6.7% 8.1% 0.74 5.5% 4.7% 0.81 AIHA 1.1% 0.0% 0.52 0.6% 2.3% 0.20 Leukocytopenia 12.0% 13.5% 0.79 24.9% 16.3% 0.21 Neutropenia 19.5% 35.1% 0.03 32.4% 44.2% 0.12 Thrombopenia 11.4% 5.4% 0.26 7.8% 0.46 Infections, unspecified 9.5% 13.0% 18.6% 0.31 Infections, bacterial 0.7% 0.02 1.9%

SOB’s Quick Survey All patients with CLL > 70 years seen by me in clinic last month: N = 14 Eligible for CLL8 trial? 3 too old, > 80 years, so N = 11 Meet creatinine clearance requirement? N = 4 So 4/14 = 29% eligible Not counting CIR score

FCR300: Progression-free & Overall Survival Median follow up time All - 9.8 yrs Alive - 11.5 yrs Proportion Surviving Events Total Median 186 300 6.5 yrs 113 300 11+ yrs Months

First-line FCR: NCI-WG Response & Bone Marrow MRD-free Status % of Patients % MRD- Negative* CR 153 65 75 nPR 29 12 4 PR 48 20 44 NR 7 3 Overall MRD 220 93 59 * Bone marrow evaluation by 4-color flow cytometry (sensitivity .01%)

First-line FCR: PFS & OS by MRD Status Progression-free Survival Overall Survival Proportion of Patients p<.0001 p=.0004 Months

First-line FCR: Multivariable Model for BM MRD-free Status (N=181) Pretreatment Characteristic p-value IGHV – Mutated .003 Rai Stage – 0-II .016 Trisomy 12 .02 No 17p del .04

FCR300: PFS by IGHV Mutation Status Group Events Total IGHV-M 33 82 IGHV-UM 114 131 Unknown 39 87 Proportion Progression-free P<.0001 Months

53rd ASH Annual Meeting, 10.-13. Dec. 2011, San Diego Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG) Anna Fink, MD1, Raymonde Busch2, Natali Pflug, MD1, Sebastian Boettcher, MD3, Dirk Winkler, MD4, Andreas Buehler, MD4, Matthias Ritgen, MD3, Kirsten Fischer, MD1, Barbara Eichhorst, MD1, Clemens-Martin Wendtner, MD1,5, Myriam Mendila, MD6, Michael K. Wenger, MD6, Hartmut Doehner, MD4, Michael Kneba, MD3, Stephan Stilgenbauer, MD4 and Michael Hallek, MD1 1Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany; 2Institute for Medical Statistics and Epidemiology, Technical University Munich, Germany; 3Campus Kiel, 2nd Dept. of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany; 4Internal Medicine III, University of Ulm, Germany; 5Department of Hematology, Oncology, Immunology, Palliative Care, Infectiology and Tropical Medicine, Hospital Munich-Schwabing, Munich, Germany; 6Pharmaceutical Division/Global Drug Dev., F. Hoffmann-La Roche Ltd., Basel, Switzerland; 53rd ASH Annual Meeting, 10.-13. Dec. 2011, San Diego Fink, et al. ASH 2011, Abstract 977

Defining High-risk for Early Progression in Patients Treated with First-line FCR (CLL8) Early progression defined as progression within 24 months of FCR MRD level of >10-2 OR MRD level of >10-4 to <10-2 plus at least one of the following three parameters (del(17p) OR TP53 mutation OR unmutated IGHV-status Fink, et al. ASH 2011, Abstract 977

PFS and OS in High-risk vs. Low-risk First-line FCR (CLL8) Progression Free Survival Low risk High risk Low risk High risk Proportion without progression Total n=143, HR n=40, LR n=103 OS High risk vs low risk Total n=143, HR n=40, LR n=103 Time since randomization in months Fink, et al. ASH 2011, Abstract 977

FCR300: Progression-free & Overall Survival Median follow up time All - 9.8 yrs Alive - 11.5 yrs Proportion Surviving Events Total Median 186 300 6.5 yrs 113 300 11+ yrs Months